Literature DB >> 28863971

Editorial commentary: Is it still important to evaluate patients with ischemic cardiomyopathy for viable dysfunctional myocardium prior to myocardial revascularization?

John M Canty1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28863971      PMCID： PMC5741496          DOI： 10.1016/j.tcm.2017.08.007

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN： 1050-1738            Impact factor:   6.677


× No keyword cloud information.
  15 in total

Review 1.  Hibernating myocardium.

Authors:  John M Canty; James A Fallavollita
Journal:  J Nucl Cardiol       Date:  2005 Jan-Feb       Impact factor: 5.952

Review 2.  Myocardial viability-State of the art: Is it still relevant and how to best assess it with imaging?

Authors:  Hena Patel; Wojciech Mazur; Kim Allan Williams; Dinesh K Kalra
Journal:  Trends Cardiovasc Med       Date:  2017-07-10       Impact factor: 6.677

3.  18F-2-deoxyglucose deposition and regional flow in pigs with chronically dysfunctional myocardium. Evidence for transmural variations in chronic hibernating myocardium.

Authors:  J A Fallavollita; B J Perry; J M Canty
Journal:  Circulation       Date:  1997-04-01       Impact factor: 29.690

Review 4.  Can Functional Testing for Ischemia and Viability Guide Revascularization?

Authors:  Lisa M Mielniczuk; Gabor G Toth; Joe X Xie; Bernard De Bruyne; Leslee J Shaw; Rob S Beanlands
Journal:  JACC Cardiovasc Imaging       Date:  2017-03

5.  Profound apoptosis-mediated regional myocyte loss and compensatory hypertrophy in pigs with hibernating myocardium.

Authors:  H Lim; J A Fallavollita; R Hard; C W Kerr; J M Canty
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

6.  Myocardial viability and survival in ischemic left ventricular dysfunction.

Authors:  Robert O Bonow; Gerald Maurer; Kerry L Lee; Thomas A Holly; Philip F Binkley; Patrice Desvigne-Nickens; Jaroslaw Drozdz; Pedro S Farsky; Arthur M Feldman; Torsten Doenst; Robert E Michler; Daniel S Berman; Jose C Nicolau; Patricia A Pellikka; Krzysztof Wrobel; Nasri Alotti; Federico M Asch; Liliana E Favaloro; Lilin She; Eric J Velazquez; Robert H Jones; Julio A Panza
Journal:  N Engl J Med       Date:  2011-04-04       Impact factor: 91.245

7.  Revascularization of chronic hibernating myocardium stimulates myocyte proliferation and partially reverses chronic adaptations to ischemia.

Authors:  Brian J Page; Michael D Banas; Gen Suzuki; Brian R Weil; Rebeccah F Young; James A Fallavollita; Beth A Palka; John M Canty
Journal:  J Am Coll Cardiol       Date:  2015-02-24       Impact factor: 24.094

8.  Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure).

Authors:  Mark C Petrie; Pardeep S Jhund; Lilin She; Christopher Adlbrecht; Torsten Doenst; Julio A Panza; James A Hill; Kerry L Lee; Jean L Rouleau; David L Prior; Imtiaz S Ali; Jyotsna Maddury; Krzysztof S Golba; Harvey D White; Peter Carson; Lukasz Chrzanowski; Alexander Romanov; Alan B Miller; Eric J Velazquez
Journal:  Circulation       Date:  2016-08-29       Impact factor: 29.690

9.  Hibernating myocardium: chronically adapted to ischemia but vulnerable to sudden death.

Authors:  John M Canty; Gen Suzuki; Michael D Banas; Fons Verheyen; Marcel Borgers; James A Fallavollita
Journal:  Circ Res       Date:  2004-03-11       Impact factor: 17.367

10.  Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy.

Authors:  Eric J Velazquez; Kerry L Lee; Robert H Jones; Hussein R Al-Khalidi; James A Hill; Julio A Panza; Robert E Michler; Robert O Bonow; Torsten Doenst; Mark C Petrie; Jae K Oh; Lilin She; Vanessa L Moore; Patrice Desvigne-Nickens; George Sopko; Jean L Rouleau
Journal:  N Engl J Med       Date:  2016-04-03       Impact factor: 91.245
View more
  1 in total

Review 1.  Myocardial stunning and hibernation revisited.

Authors:  Gerd Heusch
Journal:  Nat Rev Cardiol       Date:  2021-02-02       Impact factor: 32.419
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.